Sunday, April 11, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

DoD Seeks Medical Countermeasure Manufacturing

by Global Biodefense Staff
June 6, 2016
Bioterrorism Vaccine Countermeasures

Bioterrorism Vaccine CountermeasuresThe U.S. Department of Defense (DoD) is conducting market research to identify vaccine developers who have advanced manufacturing platforms which are adaptable to incorporating known antigens for use as a prophylaxis countermeasure against weaponizable biological agents.

Manufacturers are sought with the capability to develop processes and deliver filled/finished material that is suitable to support non-clinical Investigational New Drug (IND)-enabling studies and for use in humans up through Phase 2 clinical trials under an IND application.

Specifically, the DoD is seeking information from manufacturers with a high level of control over their manufacturing platform processes and, at the appropriate time, the willingness to partner with the DoD to potentially transfer the manufacturing process to the DoD Advanced Development Manufacturing Capability (ADMC) facility, currently residing at Nanotherapeutics Inc in Alachua, Florida.

The DOD intends to use Eastern Equine Encephalitis virus (EEEV) as a test case, and will provide information and materials pertaining to the protective antigens, critical reagents for identity testing, non-clinical challenge models, immunogenicity assays and reagents, and challenge materials.

Further details are available via Solicitation Number: EEEV2016. The response deadline is June 30, 2016.

Tags: BioterrorismJPEO-CBRNDRFIVaccines

Related Posts

What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?
Medical Countermeasures

What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?

April 8, 2021
New Initiative to Support Studies of the Bat Immune System
Funding News

New Initiative to Support Studies of the Bat Immune System

April 7, 2021
National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder
Medical Countermeasures

National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder

April 7, 2021
New Insights on Cause of Rare Anaphylaxis Following COVID-19 Vaccination
Medical Countermeasures

New Insights on Cause of Rare Anaphylaxis Following COVID-19 Vaccination

April 7, 2021
Load More

Latest News

A Virologist Explains Their Concerns About Coronavirus Variants

A Virologist Explains Their Concerns About Coronavirus Variants

April 8, 2021
What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?

What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?

April 8, 2021
New Initiative to Support Studies of the Bat Immune System

New Initiative to Support Studies of the Bat Immune System

April 7, 2021
National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder

National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder

April 7, 2021

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
  • Subscribe

© 2021 Stemar Media Group LLC